Showing results (311-320 of 323) with videos related to

Sort By:
Pageof 33
Rheumatology (Oxford, England)|July 30, 2024
Autoantibodies to joint-related peptides as predictive markers in early rheumatoid arthritisMonica Leu Agelii, Outi Sareila, Erik Lönnblom, et al.
RMD Open|November 22, 2019
Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritisUlf Lindström, Bente Glintborg, Daniela Di Giuseppe, et al.
Arthritis Research & Therapy|November 10, 2005
The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritisCarl Turesson, Daniel J Schaid, Cornelia M Weyand, et al.
Infection|January 2, 2021
HIV and SARS-CoV-2 co-infection: cross-sectional findings from a German 'hotspot'S Noe, F Schabaz, S Heldwein, et al.
Scientific Reports|May 23, 2020
Collapse dynamics of spherical cavities in a solid under shock loadingE M Escauriza, J P Duarte, D J Chapman, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 31, 2023
Autoantibodies to Disease-Related Proteins in Joints as Novel Biomarkers for the Diagnosis of Rheumatoid ArthritisErik Lönnblom, Monica Leu Agelii, Outi Sareila, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 14, 2020
Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid ArthritisJosephine A M P Amkreutz, Emma C de Moel, Lisa Theander, et al.
Rheumatology (Oxford, England)|December 28, 2020
Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritisUlf Lindström, Bente Glintborg, Daniela Di Giuseppe, et al.
Rheumatology (Oxford, England)|June 28, 2020
Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort studyRebekka Lund Hansen, Tanja Schoedt Jørgensen, Lene Dreyer, et al.
The Journal of Rheumatology|March 2, 2021
Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid ArthritisKaterina Chatzidionysiou, Merete Lund Hetland, Thomas Frisell, et al.
Pageof 33